A wet AMD biosimilar approval leads this week’s recap, plus Medicare pay updates and tips to avoid burnout and losing patients.
ODs face a $32.63 Medicare conversion factor in 2027, plus 80% payment for the lower-cost service when an E/M visit and 0-day ...
Christopher Browning, OD, and Nicholas Garn, OD, now offer cataract surgery and refractive lens exchange in their own practices. Indiana’s first OD-owned office-based surgery (OBS) suites are now open ...
According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, ...
Under the terms of the agreement, Iolyx Therapeutics has granted Théa exclusive worldwide development and commercialization rights, excluding Asia, to ILYX-002 for the treatment of ocular surface ...
Kansas, Tennessee, and Vermont expanded optometric scope in 2026, while vision plan reform and a proposed Medicare fee ...
Bita Asghari, OD, FAAO, FSLS, discusses diagnosing ocular surface inflammation, recognizing atypical keratitis, and knowing when to refer to a cornea specialist. Optometrists play an expanding role in ...
The FDA approved Lucamzi (ranibizumab-blrz; Xbrane Biopharma), a biosimilar to Lucentis (ranibizumab; Genentech), for neovascular (wet) age-related macular degeneration (AMD) and ...
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results